ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jaybe who wrote (3250)	2/26/2014 12:15:35 AM
From: tejek	Read Replies (1) of 4474

. My problem with KIT, PDGFR, VEGFR, FGFR, FLT3 or RET is why advance a candidate in late 2014 that diminishes Pona's potential. In a supposed shareholder value creating year this wouldn't make sense. I think the new candidate was expedited due to its marketable expansion of pipeline, lab expertise, and revenue potential. Footnote: Interesting that HB stated [Nature Biotech Podcast in [Sept 2013] his personal goal of seeing next two candidates into clinical trials. To me this means the second candidate (3rd gen EGFRm) will not be far behind, likely by mid-2015. Since both candidates were described in late 2012 as progressing well both could be IND ready this year. He's been talking about a new candidate for some time now. Why does it take so long to get into clinical trials?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next